CGON

Over the past six months, CG Oncology's stock has significantly appreciated. The company raised USD 380 million in an IPO in January 2024. Positive topline data from the Phase III BOND-003 trial for high-risk BCG-unresponsive NMIBC showed a 74.5% complete response rate. The timeline for topline data from the Phase III PIVOT-006 trial in intermediate-risk NMIBC has been expedited to the first half of 2026. In the first quarter of 2026, CG Oncology reported $1.1 million in revenue and a net loss of $60.2 million, with cash, cash equivalents, and marketable securities reaching $1.1 billion. The company expects to complete its BLA submission for high-risk BCG-unresponsive NMIBC by the fourth quarter of 2026. Insiders have primarily sold CGON stock, and several firms have issued "Buy" or "Outperform" ratings.